Horizon Kinetics’s Albany Molecular Research Inc AMRI Stock Holding History

Horizon Kinetics’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-56,000	Closed	-$1.22M	–	514
2017 Q2	$1.22M	Hold	56,000	–	–	0.04%	173
2017 Q1	$786K	Hold	56,000	–	–	0.02%	223
2016 Q4	$1.05M	Hold	56,000	–	–	0.03%	182
2016 Q3	$925K	Hold	56,000	–	–	0.03%	209
2016 Q2	$753K	Hold	56,000	–	–	0.02%	248
2016 Q1	$856K	Hold	56,000	–	–	0.02%	219
2015 Q4	$1.11M	Hold	56,000	–	–	0.02%	181
2015 Q3	$976K	Hold	56,000	–	–	0.02%	200
2015 Q2	$1.13M	Hold	56,000	–	–	0.02%	212
2015 Q1	$986K	Hold	56,000	–	–	0.01%	235
2014 Q4	$912K	Hold	56,000	–	–	0.01%	256
2014 Q3	$1.24M	Hold	56,000	–	–	0.02%	212
2014 Q2	$1.13M	Hold	56,000	–	–	0.01%	228
2014 Q1	$1.04M	Hold	56,000	–	–	0.01%	240
2013 Q4	$564K	Hold	56,000	–	–	0.01%	319
2013 Q3	$722K	Hold	56,000	–	–	0.01%	276
2013 Q2	$665K	Buy	+56,000	New	+$607K	0.01%	292

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Horizon Kinetics's AMRI Position: Q3 2017 in Review

Horizon Kinetics sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 56,000 shares — an estimated $1.22M sold.

Horizon Kinetics first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $1.24M in Q3 2014. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

Horizon Kinetics reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
Horizon Kinetics sold 56,000 Albany Molecular Research Inc shares in Q3 2017, an estimated $1.22M.
Horizon Kinetics first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
Horizon Kinetics's Albany Molecular Research Inc position peaked at $1.24M in Q3 2014.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Horizon Kinetics's 13F filing for Q3 2017, filed 14 Nov 2017.